Last reviewed · How we verify

NCT04461457

Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2

Completed EARLY_PHASE1 Last updated 8 July 2020
What this trial tests

EARLY_PHASE1 trial testing 211-astatine MX35 F(ab')2 in Ovarian Cancer in 12 participants. Completed in 19 January 2012.

Timeline
5 February 2005
Primary endpoint
19 March 2011
19 January 2012

Quick facts

Lead sponsorVastra Gotaland Region
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Designsequential
Maskingnone
Primary purposetreatment
Enrollment12
Start date5 February 2005
Primary completion19 March 2011
Estimated completion19 January 2012
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

Adults 18 to 85, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this alpha-radioimmunotherapy study groups of 3 patients with recurring epithelial ovarian cancer treated by salvage chemo-therapy and being in complete or good partial remission will receive one intra peritoneal infusion of 211 astatine (211At)-MX35 F(ab')2 . Patients will receive a single dose of MX35 F(ab')2 radiolabeled with increasing activity concentration of 211At in 1.0 - 2 L Extraneal® solution starting at an activity concentration of 50 megabecquerel per litre (MBq/L).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Astatine-211 based radionuclide therapy: Current clinical trial landscape.
    Albertsson P, Bäck T, Bergmark K, Hallqvist A, et al · · 2022 · cited 46× · PMID 36687417 · DOI 10.3389/fmed.2022.1076210
  2. Nutrient transporters: connecting cancer metabolism to therapeutic opportunities.
    Nwosu ZC, Song MG, di Magliano MP, Lyssiotis CA, et al · · 2023 · cited 29× · PMID 36739364 · DOI 10.1038/s41388-023-02593-x
  3. Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.
    Vanermen M, Ligeour M, Oliveira MC, Gestin JF, et al · · 2024 · cited 20× · PMID 39365487 · DOI 10.1186/s41181-024-00298-4
  4. Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment.
    Roncali L, Hindré F, Samarut E, Lacoeuille F, et al · · 2025 · cited 6× · PMID 40303349 · DOI 10.7150/thno.106081
  5. Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.
    Müller M, Pedersen NB, Shalgunov V, Jensen AI, et al · · 2026 · cited 5× · PMID 40888104 · DOI 10.1002/med.70008
  6. Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target.
    Sabanathan D, Lund ME, Campbell DH, Walsh BJ, et al · · 2021 · cited 4× · PMID 34646364 · DOI 10.1177/17588359211022918
  7. A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.
    Xu LL, Singh SK, Gaspar N, Fan J, et al · · 2026 · PMID 41900117 · DOI 10.3390/molecules31061019
  8. Current landscape and clinical progress of targeted alpha radioimmunotherapy.
    Booth OC, Dhamecha KR, Oderinde OM, Zheng QH. · · 2025 · PMID 41567834 · DOI 10.62347/getq4987

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

Other Vastra Gotaland Region trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04461457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing